Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Scott Silver

Internal Medicine Las Vegas, NV Doctor of Osteopathy

NPI 1326333071 CMS profile 60643

2010 Goldring Ave, 100, Las Vegas, NV 89106

Open in the dashboard

General payments

$1,767

94 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Scott Silver of Las Vegas, NV is reported in the CMS Open Payments database as having received $1,767 across 94 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $276 14
2023 General $224 12
2022 General $552 27
2021 General $312 19
2020 General $33 2
2019 General $372 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Silver
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Scott Silver were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Scott Silver Internal Medicine median Middle half National median
2019 $372 $159 $48–$570 $163
2020 $33 $119 $33–$402 $114
2021 $312 $135 $37–$521 $132
2022 $552 $141 $42–$496 $149
2023 $224 $149 $45–$519 $160
2024 $276 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Pfizer Inc. $738 43 payments
  2. Novartis Pharmaceuticals Corporation $354 21 payments
  3. E.R. Squibb & Sons, L.L.C. $128 7 payments
  4. Veran Medical Technologies, Inc. $107 1 payment
  5. Intuitive Surgical, Inc. $106 1 payment
  6. Novo Nordisk Inc $100 6 payments
  7. AbbVie, Inc. $37 2 payments
  8. Amarin Pharma Inc. $33 2 payments
  9. Janssen Pharmaceuticals, Inc $31 2 payments
  10. Dexcom, Inc. $30 2 payments
  11. Other $104 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,766 93 payments
  2. Education $2 1 payment
Products named General payments · program years 2019–2024
  1. ELIQUIS Cardiovascular;Metabolic Disease $712 41 payments
  2. NURTEC ODT $354 17 payments
  3. PAXLOVID $340 16 payments
  4. ENTRESTO Cardiovascular $242 15 payments
  5. Spin $107 1 payment
  6. Da Vinci Surgical System $106 1 payment
  7. ELIQUIS Cardiovascular $104 6 payments
  8. ENTRESTO Cardiology/Vascular Diseases $90 5 payments
  9. ZAVZPRET $86 4 payments
  10. RYBELSUS $78 5 payments
  11. Other $557 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

664

Median for Internal Medicine: 777

Drug cost

$22,288

Median for Internal Medicine: $73,373

Branded share of claims

32.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 36 $9,874
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 49 $1,943
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 28 $1,243
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 16 $1,158
Divalproex Sodium Generic 18 $790
Heparin Sodium Heparin Sodium,porcine Brand 26 $759
Oxycodone Hcl Generic 37 $584
Atorvastatin Calcium Generic 39 $472
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 18 $437
Hydralazine Hcl Generic 21 $397

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$417,212

Medicare's payments for the services billed

Medicare patients

849

Average age 71

Services billed

5,352

437 women, 412 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 57%
Ischemic heart disease 50%
Heart failure 46%
Chronic kidney disease 46%
COPD 43%
Depression 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $58
$58 36 —
NURTEC ODT
  • PFIZER INC. $58
$58 — —
PAXLOVID
  • PFIZER INC. $55
$55 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $25
$25 — —
ZAVZPRET
  • PFIZER INC. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

94 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record